These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 37375183)
1. Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents. Han MJ; Pan M; Xiao G; Yuan Y; Chen S; Zou Z Molecules; 2023 Jun; 28(12):. PubMed ID: 37375183 [TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis. Ehrens A; Lunde CS; Jacobs RT; Struever D; Koschel M; Frohberger SJ; Lenz F; Fendler M; Turner JD; Ward SA; Taylor MJ; Freund YR; Stefanakis R; Easom E; Li X; Plattner JJ; Hoerauf A; Hübner MP PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007957. PubMed ID: 31986143 [TBL] [Abstract][Full Text] [Related]
3. Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis. Jacobs RT; Lunde CS; Freund YR; Hernandez V; Li X; Xia Y; Carter DS; Berry PW; Halladay J; Rock F; Stefanakis R; Easom E; Plattner JJ; Ford L; Johnston KL; Cook DAN; Clare R; Cassidy A; Myhill L; Tyrer H; Gamble J; Guimaraes AF; Steven A; Lenz F; Ehrens A; Frohberger SJ; Koschel M; Hoerauf A; Hübner MP; McNamara CW; Bakowski MA; Turner JD; Taylor MJ; Ward SA J Med Chem; 2019 Mar; 62(5):2521-2540. PubMed ID: 30730745 [TBL] [Abstract][Full Text] [Related]
4. Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance. Paukner S; Riedl R Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27742734 [TBL] [Abstract][Full Text] [Related]
5. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and antibacterial activity of pleuromutilin derivatives. Liu HX; Yao WY; Cui G; Zhou J; Yan H; Guo H; Wang YW; Zhang Y Chem Biol Drug Des; 2024 Jun; 103(6):e14554. PubMed ID: 38806405 [TBL] [Abstract][Full Text] [Related]
7. Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens. Hirokawa Y; Kinoshita H; Tanaka T; Nakata K; Kitadai N; Fujimoto K; Kashimoto S; Kojima T; Kato S J Med Chem; 2008 Apr; 51(7):1991-4. PubMed ID: 18330977 [TBL] [Abstract][Full Text] [Related]
8. Recent advances in developing modified C14 side chain pleuromutilins as novel antibacterial agents. Liu Y; Zhou Q; Huo Y; Sun X; Hu J Eur J Med Chem; 2024 Apr; 269():116313. PubMed ID: 38503168 [TBL] [Abstract][Full Text] [Related]
10. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia. Lee YR; Jacobs KL Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia. Perry W; Golan Y Future Microbiol; 2019 Jul; 14():927-939. PubMed ID: 31333062 [TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of Pleuromutilin Derivatives as Antibacterial Agents Using Quantitative Structure-Activity Relationship Model. Zhang J; Liu Q; Zhao H; Li G; Yi Y; Shang R Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396934 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel pleuromutilin derivatives containing piperazine and 1,2,3-triazole linker. Zhang GY; Zhang Z; Li K; Liu J; Li B; Jin Z; Liu YH; Tang YZ Bioorg Chem; 2020 Dec; 105():104398. PubMed ID: 33137559 [TBL] [Abstract][Full Text] [Related]
14. A modular and enantioselective synthesis of the pleuromutilin antibiotics. Murphy SK; Zeng M; Herzon SB Science; 2017 Jun; 356(6341):956-959. PubMed ID: 28572392 [TBL] [Abstract][Full Text] [Related]
15. Pleuromutilin derivatives having a purine ring. Part 2: influence of the central spacer on the antibacterial activity against Gram-positive pathogens. Hirokawa Y; Kinoshita H; Tanaka T; Nakamura T; Fujimoto K; Kashimoto S; Kojima T; Kato S Bioorg Med Chem Lett; 2009 Jan; 19(1):170-4. PubMed ID: 19028096 [TBL] [Abstract][Full Text] [Related]
16. Pleuromutilin derivatives having a purine ring. Part 1: new compounds with promising antibacterial activity against resistant Gram-positive pathogens. Hirokawa Y; Kinoshita H; Tanaka T; Nakamura T; Fujimoto K; Kashimoto S; Kojima T; Kato S Bioorg Med Chem Lett; 2008 Jun; 18(12):3556-61. PubMed ID: 18511280 [TBL] [Abstract][Full Text] [Related]
17. Antibacterial Activity and Pharmacokinetic Profile of a Promising Antibacterial Agent: 22-(2-Amino-phenylsulfanyl)-22-Deoxypleuromutilin. Zuo X; Fang X; Zhang Z; Jin Z; Xi G; Liu Y; Tang Y Molecules; 2020 Feb; 25(4):. PubMed ID: 32079232 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059 [TBL] [Abstract][Full Text] [Related]
19. An antimycobacterial pleuromutilin analogue effective against dormant bacilli. Lemieux MR; Siricilla S; Mitachi K; Eslamimehr S; Wang Y; Yang D; Pressly JD; Kong Y; Park F; Franzblau SG; Kurosu M Bioorg Med Chem; 2018 Sep; 26(17):4787-4796. PubMed ID: 30145051 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel pleuromutilin derivatives possessing acetamine phenyl linker. Jin Z; Wang L; Gao H; Zhou YH; Liu YH; Tang YZ Eur J Med Chem; 2019 Nov; 181():111594. PubMed ID: 31419741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]